100
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Estimated prevalence of hereditary cancers and the need for surveillance in a Norwegian county, Telemark

, , , , , & show all
Pages 71-79 | Received 31 Dec 2004, Published online: 08 Jul 2009

References

  • Watson P, Lynch HT. The tumor spectrum in HNPCC. Anticancer Res 1994; 14: 1635–9
  • Claus EB, Schildcraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77: 2318–24
  • Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214–8
  • Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310–6
  • Lynch HT, de la Chapelle A. Genetic susceptibilty to non-polyposis colorectal cancer. J Med Genet 1999; 36: 801–18
  • Møller P, Borg A, Heimdal K, Apold J, Vallon-Christersson J, Hovig E, et al. The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series. Eur J Cancer 2001; 37: 1027–32
  • Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 1998; 129: 786–96
  • Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyoposis colorectal cancer. Gastroenterology 2000; 118: 829–34
  • Møller P, Reis MM, Evans G, Vasen H, Haites N, Anderson E, et al. Efficacy of early diagnosis and treatment in women with a family history of breast cancer. Dis Markers 1999; 15: 179–86
  • Møller P, Borg Å, Evans G, Haites N, Reis MM, Vasen H, et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumor characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002; 101: 555–9
  • Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71
  • Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–92
  • Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75: 1215–25
  • Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, et al. Mutation in the DNA mismatch repair gene homologue MLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368: 258–61
  • Papadopoulos N, Nicolaides NC, Wei YF, Ruben S, Carter KC, Rosen CA, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263: 1625–9
  • Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, et al. Mutation of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371: 75–80
  • Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, Abe R, et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997; 57: 3920–3
  • Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997; 17: 271–2
  • Møller P, Heimdal K, Apold J, Fredriksen Å, Borg Å, Hovig E, et al. Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 2001; 37: 2428–34
  • Arason A, Jonasdottir A, Barkardottir RB, Bergthorsson JT, Teare MD, Easton DF, et al. A population study of mutations and LOH at breast cancer gene loci in tumors from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet 1998; 35: 446–9
  • Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996; 56: 3663–5
  • Nyström-Lathi M, Kristo P, Nicolaides NC, Chang S-Y, Aaltonen LA, Moisio A-L, et al. Founding mutations and Alu-mediated recombination in hereditary cancer. Nat Med 1995; 1: 1203–6
  • Nyström-Lathi M, Wu Y, Moiso A-L, Hofstra RMW, Osinga J, Mecklin J-P, et al. DNA mismatch gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Hum Mol Genet 1996; 5: 763–9
  • Holmberg M, Kristo P, Chadwicks RB, Mecklin JP, Järvinen HJ, de la Chapelle A, et al. Mutation sharing, predominant involvement of the MLH1 gene and description of four novel mutations in hereditary non-polyposis colorectal cancer. Hum Mutat 1998; 11: 482
  • Douglas F, O'Dair L, Robinson M, Evans DGR, Lynch SA. The accuracy of diagnoses as reported in families with cancer: a retrospective study. J Med Genet 1999; 36: 309–12
  • Statistics Norway. http://www.ssb.no/.
  • Bretthauer M, Gondal G, Larsen IK, Carlsen E, Eide TJ, Grotmol T, et al. Design, organization and management of a controlled population screening study for detection of colorectal neoplasia. Scand J Gastroenterol 2002:568–73.
  • Vasen HFA, Mecklin J-P, Meera Khan P, Lynch HT. The International Collaborative Group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424–5
  • Vasen FA, Watson P, Mecklin J-P, Lynch HT. ICG-HNPCC. New clinical criteria for hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999; 116: 1453–6
  • Møller P. Genetic cancer: a challenge and a possible strategy. J Cancer Care 1993; 2: 94–9
  • Møller P, Evans G, Haites N, Vasen H, Reis MM, Anderson E, et al. Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from Biomed 2 demonstration programme on inherited breast cancer. Dis Markers 1999; 15: 207–11
  • Norwegian Gastrointestinal Cancer Group (NGICG). Colorectal cancer and anal cancer. Oslo: The Norwegian Cancer Society; 1999. pp. 17–21 (Norwegian).
  • Wijnen JT, Vasen HFA, Khan PM, Zwinderman AH, van der Klift H, Mulder A, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Eng J Med 1998; 339: 511–8
  • Loukola A, de la Chapelle A, Aaltonen LA. Strategies for screening for hereditary non-polyposis colorectal cancer. Genetics 1999; 36: 819–22
  • Bisgaard ML, Jäger AC, Myrhøj T, Bernstein I, Nielsen FC. Hereditary non-polyposis colorectal cancer (HNPCC): phenotype–genotype correlation between patients with and without identified mutation. Hum Mut 2002; 20: 20–7
  • Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 1996; 56: 4836–40
  • de Leeuw WJF, Dierssen JW, Vasen HFA, Wijnen JT, Kenter GG, Meijers-Heijboer H, et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumors from HNPCC patients. J Pathol 2000; 192: 328–35
  • Katballe N, Christensen M, Wikman FP, Ørntoft TF, Laurberg S. Frequency of hereditary non-polyposis colorectal cancer in colorectal cancer patients. Gut 2001; 50: 43–51
  • Vasen HF, Taal BG, Nagengast FM, Griffioen G, Menko FH, Kleibeuker JH, et al. Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer 1995; 31A: 1145–8
  • de Vos tot Nederveen Cappel, Nagengast FM, Griffioen G, Menko F, Taal BG, Kleibeuker JH, et al. Surveillance for hereditary nonpolyposis colorectal cancer. A long-term study on 114 families. Dis Colon Rectum 2002; 45: 1588–94
  • Vasen HF, van Ballegooijen M, Buskens E, Kleibeuker, Taal BG, Griffioen G, et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998; 82: 1632–7
  • Arver B, Haegermark A, Platten U, Lindblom A, Brandberg Y. Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: a 12-month follow-up. Fam Cancer 2004; 3: 109–16
  • Lerman C, Schwartz MD, Miller SM, Daly M, Sands C, Rimer BK. A randomized trial of breast cancer risk counseling: Interacting effects of counseling, educational level, and coping style. Health Psychol 1996; 15: 75–83
  • Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, et al. JAMA 1996; 275: 1885–92
  • Bish A, Sutton S, Jacobs C, Levene S, Ramirez A, Hodgson S. Changes in psychological distress after cancer genetic counselling: a comparison of affected and unaffected women. Br J Cancer 2002; 86: 43–50
  • Collins V, Halliday J, Warren R, Williamson R. Cancer worries, risk perceptions and associations with interest in DNA testing and clinical satisfaction in a familial colorectal cancer clinic. Clin Genet 2000; 58: 460–8
  • Keller M, Jost R, Mastromarino Haunstetter C, Kienle P, Knaebel HP, Gebert J, et al. Comprehensive genetic counselling for families at risk for HNPCC: impact on distress and perceptions. Genet Testing 2002; 6: 291–302
  • Kerber RA, Slatery ML. Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J of Epidemiol 1997; 146: 3244–8
  • Ivanovich J, Babb S, Goodfellow P, Mutch D, Herzog T, Rader J, et al. Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. Clin Cancer Res 2002; 8: 1849–56
  • Hoff G. CRC screening: review of the evidence and suggestions on when and how to move on from randomized trials to screening programmes. Scand J Gastroenterol 2004; 39: 99–103
  • Stormorken AT, Müller W, Lemkemeyer B, Apold J, Wijnen J, Fodde R, et al. Prediction of the outcome of genetic testing in HNPCC kindreds using the revised Amsterdam criteria and immunohistochemistry. Fam Cancer 2001; 1: 169–73
  • Aitken J, Bain C, Ward M, Siskind V, MacLennan R. How accurate is self-reported family history of colorectal cancer?. Am J Epidemiol 1995; 141: 863–71
  • Katballe N, Juul S, Christensen M, Ørntoft TF, Wikman FP, Laurberg S. Patient accuracy of reporting on hereditary non-polyposis colorectal cancer-related malignancy in family members. Br J Surg 2001; 88: 1228–33
  • Mitchell RJ, Brewster D, Campbell H, Porteous MEM, Wyllie AH, Bird CC, et al. Accuracy of reporting of family history of colorectal cancer. Gut 2004; 53: 291–5
  • Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000;83:1301–8.
  • Mecklin JP, Jarvinen HJ, Hakkiluoto A, Hallikas H, Hiltunen KM, Harkonen N, et al. Frequency of hereditary nonpolyposis colorectal cancer. A prospective multicenter study in Finland. Dis Colon Rectum 1995; 38: 588–93
  • Evans DG, Walsh S, Jeacock J, Robinson C, Hadfield L, Davies DR, et al. Incidence of hereditary non-polyposis colorectal cancer in a population based study of 1137 consecutive cases of colorectal cancer. Br J Surg 1997; 84: 1281–5
  • de Leon MP, Pedroni M, Benatti P, Percesepe A, Di Gregorio C, Foroni M. Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis. Gut 1999; 45: 32–8
  • Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Eng J Med 1998; 338: 1481–7
  • Cornaggia M, Tibiletti MG, Albarello L, Taboreli M, Dalla Longa E, Capella C. Low incidence of hereditary nonpolyposis colorectal cancer syndrome in a selected area of the Lombardy Cancer Registry. Tumori 2000; 86: 439–44
  • Olsson L, Lindblom A. Family history of colorectal cancer in a Swedish county. Fam Cancer 2003; 2: 87–93
  • Stormorken A, Müller W, Lindblom A, Heimdal K, Aase S, Bowitz-Lothe IM, et al. The inframe MSH2 codon 596 deletion is linked with HNPCC and associated with lack of MSH2 protein in tumors. Fam Cancer 2003; 2: 9–13
  • Wagner A, Hendriks Y, Meijers-Heijboer EJ, de Leuw WJ, Morreau H, Hofstra R, et al. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet 2001; 38: 318–22
  • Schweizer P, Moiso AL, Kuismanen SA, Truninger K, Vierumaki R, Salo R, et al. Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas in hereditary nonpolyposis colorectal cancer. Cancer Res 2001; 61: 2813–5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.